Work

Table S2 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma

Year: 2023

Type: other

Abstract: Treatment-emergent adverse events reported in {greater than or equal to}10% patients.

DOI: 10.1158/1535-7163.22521156

Authors: Javier Martín-Broto, Antonio López Pousa, Andrew S. Brohl, Brian A. Van Tine, Benjamin Powers, Silvia Stacchiotti, Jean-Yves Blay, James S. Hu, Gerard J. Oakley, Hong Wang, Anna M. Szpurka, Donna E. Levy, Gary Mo, Matteo Ceccarelli, Robin L. Jones

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362614222

Cites:

Cited by:

Related to: 10